The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Open accessAbstract
The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of gastrointestinal or genitourinary bleeding, in the absence of strong drug–drug interactions or of gastrointestinal absorption impairment; (3) LMWHs or direct oral anticoagulants for a minimum of 6 months to treat cancer-associated thrombosis; (4) extended prophylaxis (4 weeks) with LMWHs to prevent postoperative venous thromboembolism after major abdominopelvic surgery in patients not at high risk of bleeding; and (5) primary prophylaxis of venous thromboembolism with LMWHs or direct oral anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with anticancer therapy and have a low risk of bleeding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Self-citationCOVID-19 and its implications for thrombosis and anticoagulation
Connors, J. M., & Levy, J. H. (2020) · Blood · doi:10.1182/blood.2020006000 · Cited by 2,369
Self-citationEdoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Self-citationYoung, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
Self-citationApixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915103 · Cited by 1,067
Self-citationApixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852
Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., & Farge, D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1729 · Cited by 796
Self-citationVenous thromboembolism in cancer patients: a population-based cohort study
Mulder, F. I., Horváth-Puhó, E., van Es, N., van Laarhoven, H. W. M., Pedersen, L., Moik, F., Ay, C., Büller, H. R., & Sørensen, H. T. (2021) · Blood · doi:10.1182/blood.2020007338 · Cited by 723
Self-citationRivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814630 · Cited by 719
Self-citation
Metadata
- Authors
- Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., Antic, D., Casais, P., Guillermo Esposito, M. C., Ikezoe, T., Abutalib, S. A., Meillon-García, L. A., Bounameaux, H., Pabinger, I., Douketis, J., Ageno, W., Ajauro, F., Alcindor, T., Angchaisuksiri, P., Arcelus, J. I., Barba, R., Bazarbachii, A., Bellesoeur, A., Bensaoula, O., Benzidia, I., Bita, D., Bitsadze, V., Blickstein, D., Blostein, M., Bogalho, I., Brandao, A., Calado, R., Carpentier, A., Ceresetto, J. M., Chitsike, R., Connault, J., Correia, C. J., Crichi, B., De Paula, E. V., Demir, A. M., Deville, L., Doucet, L., Dounaevskaia, V., Durant, C., Ellis, M., Emmerich, J., Falanga, A., Font, C., Gallardo, E., Gary, T., Gonçalves, F., Gris, J.-C., Hayashi, H., Hij, A., Jara-Palomares, L., Jiménez, D., Khizroeva, J., N'Guessan, M., Langer, F., Le Hello, C., Le Maignan, C., Lecumberri, R., Lee, L. H., Liederman, Z., Lopes dos Santos, L., Machado, D. H., Makatsariya, A., Maneyro, A., Marjanovic, Z., Milhaileanu, S., Monreal, M., Morais, S., Moreira, A., Mukai, M., Ndour, A., Correa Oliveira, L., Otero-Candelara, R., Tostes Pintao, M. C., Posch, F., Prilollet, P., Rafii, H., Dias Ribeiro, D., Riess, H., Righini, M., Robert-Ebadi, H., Rothschild, C., Roussin, A., Rueda Camino, J. A., Ruiz-Artacho, P., Saharov, G., Santos, J., Sebuhyan, M., Shamseddine, A., Spectre, G. S., Taher, A., Trujillo-Santos, J., Tzoran, I., Villiers, S., Wong, R., Yamashita, Y., Yannoutsos, A., & Yasuda, C.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 23
- Issue
- 7
- Pages
- e334-e347
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4283644627
- Cited by
- 486
- References
- 68
- FWCI
- 82.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00160-7
- The paper
- Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., Antic, D., Casais, P., Guillermo Esposito, M. C., Ikezoe, T., Abutalib, S. A., Meillon-García, L. A., Bounameaux, H., Pabinger, I., Douketis, J., . . . Yasuda, C. (2022). 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00160-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.